The human microbiota represents an important reservoir of antibiotic resistance. Moreover, the majority of antibiotics are prescribed in primary care. For this reason, we assessed the prevalence and antibiotic resistance of nasal carriage strains of Streptococcus pneumoniae, the most prevalent bacterial causative agent of community-acquired respiratory tract infections, in outpatients in nine European countries. Nasal swabs were collected between October 2010 and May 2011, from 32,770 patients, recruited by general practices in nine European countries. Overall prevalence of S. pneumoniae nasal carriage in the nine countries was 2.9%. The carriage was higher in men (3.7%) than in women (2.7%). Children (4-9 years) had a higher carriage prevalence (27.2%) compared with those older than 10 years (1.9%). The highest resistance observed was to cefaclor. The highest prevalence of multidrug resistance was found in Spain and the lowest prevalence was observed in Sweden.
Streptococcus pneumoniae is an important causative agent of community-acquired pneumonia, otitis media, bacteremia and meningitis, especially in immunocompromised patients, young children and elderly individuals [1] . The upper respiratory tract is the main ecological niche of S. pneumoniae [2] . The colonization rates range, depending on age, between 3 and 60% [3, 4] and depend on geographic area, age, genetic background and socioeconomic status of the host [1] . The introduction of pneumococcal conjugate vaccines has led to a major decrease in pneumococcal carriage and the prevalence of pneumococcal-related diseases [5] . Depending on the vaccine used, emergence of new colonizing serotypes has been observed that have replaced the vaccine serotypes [6, 7] . Many host, environment and microbiological factors play a role in the increase of susceptibility to carry S. pneumoniae. One example of the microbiological factors is coinfection with influenza virus. Several reports have observed pneumococcal transmission via contact of a nonpneumococcal carrier with infected respiratory secretion of an influenza infected pneumococcal carrier [8] , or by person-to-person contact [9] . Most population studies conducted thus far have focused on nasopharyngeal carriage in children [10] , on the prevalence of invasive isolates [1, 5, 7] and on the effectiveness of vaccination strategies [6, [11] [12] [13] [14] . Pneumococcal carriage in adults has hardly been described, despite the fact that colonization is essential to understand bacterial epidemiology and to assess the effectiveness of preventive strategies [15] . During the last few decades, antimicrobial drug resistance has increased worldwide [16] . The human microbiota is generally considered as the main reservoir for antibiotic resistant genes and resistant microorganisms [17, 18] . The acquisition of antibiotic resistance in this environment is enhanced by the enormous potential of genomic exchange and mutations [19] . One of the aims of the APRES study, was to assess the prevalence and antibiotic resistance of nasal carriage of S. aureus and S. pneumoniae in general practice patients and to compare antibiotic resistance patterns of these isolates [20] with different antibiotic prescription policies. The results ofS. aureus analyses have been described before [21] . Here, we report the results of the prevalence and antibiotic resistance of S. pneumoniae carriage in the participating countries.
MATERIALS & METHODS

• Patient population
The study design was described previously by van Bijnen et al. [20] . In short, 20 general practitioners (GP) were recruited per country, by national GP networks in nine European countries (Austria, Belgium, Croatia, France Hungary, Spain, Sweden, The Netherlands and the UK), and aimed to each provide 200 nasal swabs, from patients older than 4 years, with the exception of the UK where patients were 18 years or older (due to ethical committee constraints). To be included in the study, patients should have visited the practice for a noninfectious condition, not used antibiotics nor been hospitalized in the 3 months preceding the swab collection. Immunocompromised patients, as well as nursing home residents, were excluded. Included patients were sampled consecutively. Information of the participating patients was derived from a questionnaire and included age, gender, profession (livestock farming, working in healthcare or in day care/nursery school), the number of GP visits during the last year, living with children younger than 5 years (other than the index patient), suffering from a chronic skin condition and vaccination against pneumococci and/or influenza ( Prior to the start of the study, GPs received a protocol for sampling the nasal swabs [21] . Isolation and identification of S. pneumoniae was performed in a national microbiological laboratory in each participating country except for France. These swabs were analyzed in the microbiological laboratory of Maastricht University Medical Center ([MUMC], The Netherlands), because no laboratory in France was prepared to perform these analyses. All (putative) pneumococci isolated at the national laboratories were kept frozen in skimmed milk at -80oC and sent at the end of the study period on dry ice to the laboratory in Maastricht for antibiotic susceptibility testing. The antibiotic resistance of the isolates was performed with microdilution for cefuroxime, cefaclor, ceftazidime, clarithromycin, clindamycin, ciprofloxacin, moxifloxacin, penicillin, tetracycline and trimethroprim-sulfamethoxazole. The control strain was S. pneumoniae ATCC 49619. Invalid results due to nonhomogenous growth were repeated twice. The method used was in accordance with EUCAST guidelines and EUCAST epidemiological cutoffs were used as resistance breakpoints [22] . Patients with incomplete demographic information or laboratory data, as well as erroneous samples (no bacterial growth noted at laboratory analysis), were excluded from the analyses.
• Statistical analysis Results were analyzed using the PASW software package 19.0. A p-value of <0.05 was considered as statistically significant. To determine pneumococcal carriage determinants odd ratios (OR)s were calculated. OR was defined as the cross-product ratio of the numbers shown in the two-by-two contingency table of flu vaccination, pneumococcal vaccination, occupation, having a chronic skin disease and living with other young children. The total number of patients who answered the specific question was used as the denominator. To account for nonrandom clustering of our data at family level and to control whether age and gender affect the pneumococcal carriage prevalence, a three level multilevel logistic regression model (country, GP and patient) was estimated using MLN-Software for N-level analysis package. Multidrug resistance (MDR) was defined as being resistant to three or more classes of antibiotics. The statistical analysis was made on two age groups: <10 years and ≥10 years. This cutoff was used to differentiate young children versus the older ones and adults as after 10 years of age pneumococcal carriage was stable [1] .
• Role of the funding source The sponsor of this study had no role in study design, data collection, data analysis data interpretation or writing of this report. The corresponding author had full access to all the data on the study and had final responsibility for the submission for publication, following agreement from all authors.
RESULTS
The number of participants ranged between 3132 in Belgium and 4017 in Hungary, resulting in a total of 32,770 patients recruited (Table 1) . Patients who did not meet the inclusion criteria because of their demographic characteristics, or incorrect sampling were excluded from the analysis [21] resulting in a total of 32,161 patients available for the data analysis.
[TABLE 1]
• Prevalence of nasal carriage The overall crude prevalence of S. pneumoniae nasal carriage was 2.9% (n = 937), and ranged from 1.2% in Austria (n = 38) and the UK (n = 36) to 4.4% in France (n = 170). The prevalence of S. pneumoniae carriage was higher in men (3.7%; 95% CI: 3.4-4.0) than in women (2.7%; 95% CI: 2.1-2.5). Children (4-9 years) had a higher carriage prevalence (27.2%; 95% CI: 24.7-29.6) compared with those older than 10 years (1.9%; 1.8-2.1). The highest carriage rate in the 4-9 year old was in Spain (24.0%) followed by France (22.2%) ( Table 2 ).
• Vaccination rates Immunization strategies against S. pneumoniae and seasonal influenza and pandemic influenza A virus differed between the nine participating countries. Variation in pneumococcal immunization included vaccination strategy (recommended or voluntary, universal or risk groups only), vaccine type, vaccination schedule, administrated doses and targeted groups. Seasonal influenza and pandemic Flu A immunization differed in targeted groups and clinical risk indications. Spain had the highest overall pneumococcal vaccination rate with 29.2% (46.4% in children younger than 9 years, and 28.3% in adolescent and adults), whereas Croatia had the lowest one with an overall rate of 0.7% (3.2% in patients younger than 9 years and 0.6% in patients of 10 years or older). France had the highest vaccination rate in children <9 years old (46.7%). Overall, 11.6% of all participating patients were vaccinated (Table 3 ).
• Determinants of nasal carriage Living with children younger than 5 years of age (or other children if the individual is a child <5 years old), resulted in a four-fold increased risk to carry S. pneumoniae (OR: 3.92; 3.41-4.50). In all participating countries, patients vaccinated against S. pneumoniae had a (nonsignificant) higher prevalence of pneumococcal carriage. The carriage prevalence among the vaccinated group was 3.5%, whereas in the unvaccinated patients this was 2.9% (OR: 1.2; 0.99-1.48). Seasonal and pandemic influenza A vaccination had no effect on the nasal pneumococcal carriage.
[TABLE 2] [TABLE 3]
• Antibiotic resistance Antibiotic resistance results were available for 928 (99.0%) of 937 S. pneumoniae isolates. Resistance to cefaclor was most common: overall 52.3% and ranging between 30.6% in the UK and 77.3% in Belgium. No resistance was observed for moxifloxacin and ciprofloxacin. Tetracycline showed the highest intercountries variability ranging between 1.9% in Sweden and 29.9% in Spain (Table 4 ). The most frequently used antibiotics in outpatients were penicillin, macrolides and tetracycline [14] . These antibiotics showed a resistance that ranged between 3.9% (Sweden) and 31.7% (Spain) for penicillin, 1.9% (Sweden) and 29.3% (Spain) for clarythromycin, and 1.9% (Sweden) and 29.9% (Spain) for tetracycline (Table 5 ).
• MDR Spain had the highest prevalence of MDR (resistance for three or more classes), in other words, 50.4%, (n = 63). The lowest percentage was observed in Sweden with 3.8% (n = 2). Thirty isolates were resistant to six classes, of which ten were from Croatia. Overall, 27 of these 30 isolates were resistant to all tested antibiotics, except for moxifloxacin and ciprofloxacin and three were resistant to all tested antibiotics. The most prevalent MDR was resistance to five classes (n = 70). The most common combination was resistance to cephalosporines (cefaclor, cefuroxime and ceftazidime), macrolides fluoroquinolone, penicillin and tetracycline (n = 40). Most of these isolates were isolated in France (n = 17) and Spain (n = 16).
[ 
DISCUSSION
In this study, nasal samples from more than 32,000 outpatients from nine European countries were collected and analyzed. The overall S. pneumoniae carriage prevalence was 2.9% and resistance to cefaclor was the most common among the isolates with 52.3%. Of all resistant isolates, 19.4% were nonsusceptible to penicillin. MDR was observed in 33.9%, ranging from 3.8% in Sweden to 50.4% in Spain. To the best of our knowledge, our study is the first to compare the prevalence and antibiotic resistance of commensal S. pneumoniae in healthy outpatients aged 4+ in several European countries. For this aim, existing GP networks were involved for patient recruitment. In addition, standardized and validated protocols were used to prevent inter laboratory differences. Our study has some limitations. For logistic reasons, in other words, feasibility to perform a study in nine different countries with 20 different general practitioners we choose to take nasal swabs instead of nasopharyngeal ones. In all swabs, even in the nasal swabs from France that were sent to Maastricht, the prevalence was in accordance to the expected one [23] . Furthermore, based on these observations, we may conclude that taken nasal swabs do not influence the results negatively. Another limitation is that, due to ethical constraints, the lower age limit for eight countries was 4 years of age, for the UK 18 years. This hampers the assessment of pneumococcal carriage and the antibiotic resistance in the lowest age group (<4 years). Finally, we did not collect clinical data, such as among others comorbidities and recent hospitalization. A wide variation in pneumococcal carriage prevalence was found among the participating countries. One of the major factors that influence pneumococcal colonization is the vaccination strategy, including vaccine type, whether vaccine was given to all children >2 years, universal or restricted to clinical risk groups only, such as patients suffering from chronic respiratory disease or cardiovascular disease (risk based), if the implementation of a vaccine was followed by a catch-up pneumococcal vaccination and the number of doses given. The high carriage prevalence in Sweden might be explained by the late introduction of vaccination to the national immunization program (2009). The introduction of the vaccine without a catch up campaign [24] does not allow individuals who exceeded the immunization age to still be vaccinated. In Croatia and Spain pneumococcal vaccine was given only to patients belonging to specific risk groups. This strategy reduces the number of vaccinated individuals and might increase the number of colonized patients. In Belgium, Croatia and The Netherlands, only PCV-7 vaccine is used [24] . The emergence of nonvaccine serotypes after the introduction of this vaccine (replacement phenomenon) might explain the high prevalence of pneumococcal carriage in these countries [5] . No significant difference was noticed between carriage prevalence in vaccinated and unvaccinated individuals. Our results support earlier studies with comparable outcomes. In a carriage study carried on 683 subjects from 217 households in England and Wales, van Hoek et al. found no change in pneumococcal carriage and a decrease of PCV7 vaccine serotypes transmission in vaccinated and unvaccinated individuals 6 years after the introduction of PCV7 vaccine, compared with carriage prevalence before the introduction of this vaccine [25] . In another carriage study, performed by Principi et al., enrolling 2076 children and adolescents from Italy, it was found that pneumococcal prevalence was higher in vaccinated individuals than in unvaccinated ones [26] . Moreover, they found that the prevalence vaccine serotypes was comparable to this nonvaccine serotypes, suggesting no role of serotypes replacement. Taken together with these results, our results might be explained by the emergence of none-vaccine serotypes that cocirculated but were suppressed by vaccine serotypes. Another explanation is the possibility that the protection effect of vaccination against pneumococcal carriage might decrease over the time, allowing a re-emergence of vaccine serotypes in vaccinated patients. In two separate mice model studies, researchers suggested that influenza virus infection enhanced the carriage of S. pneumoniae by an increase in pneumococcal load in carriers and the increase of susceptibility in influenza infected cohoused subjects [27, 28] . This suggests that influenza vaccination, by reducing the spread of infected droplets, might reduce pneumococcal transmission and, consequently, pneumococcal carriage. However, our data did not confirm this suggestion. In this study, a large variability was found between the participating countries in resistance prevalence to the commonly used antimicrobial agents in outpatients (penicillin, macrolide and tetracycline). Belgium, France, Spain and Croatia that in 2010 had a penicillin consumption of 16.3, 15.6, 12.6 and 9.5 defined daily dose (DDD) per 1000 inhabitants per day, respectively [29] , had the highest rate of antibiotic resistance to this antibiotic class. The Netherlands, with a penicillin consumption of 4.4 DDD per 1000 inhabitants per day [29] , had one of the lowest penicillin resistance. In Sweden, despite the higher rate of penicillin consumption compared with The Netherlands (7.1 DDD per 1000 inhabitants per day) [29] , the resistance rate to this agent was the lowest. This might be explained by the use in Sweden of narrow spectrum penicillins (more than 60% of the used penicillins). Furthermore, our data showed a high resistance to clarithromycin in Croatia. The consumption of this agent represents, with roxithromycin, more than 30% of the macrolides, lincosamides and streptogramin use in Croatia [30] . Differences in antibiotic consumption between the participating countries might not be the only explanation of the resistance rate variations. In fact, Spain with tetracycline consumption of 0.7 DDD per 1000 inhabitants per day [29] , has the highest resistance rate, whereas Sweden with a more than four-fold consumption (3.3 DDD per 1000 inhabitants per day) [29] , had the lowest resistance prevalence. These results underscore that other factors than antibiotic pressure, socioeconomic, behavioral and cultural determinants and differences in healthcare policies among the participating countries [31] , as well as clonal spread of resistant microorganisms [32] and antibiotic cross-resistance between members of antibiotic classes [33] might influence antibiotic resistance prevalence. Our study highlights the prevalence of antibiotic resistant S. pneumoniae carriage strains in the outpatient setting in nine European countries. These data are important to make a rational empiric choice and to create antibiotic prescription guidelines for the treatment of S. pneumoniae by GPs (i.e., the outpatient setting). As the majority of human antibiotic use is prescribed outside healthcare settings [16, 34] , optimal use of antibiotics based on actual antibiotic resistance data is important to support the control of antibiotic resistance problem. Professionals involved in the setup/reviewing of existing national antibiotic prescription guidelines have to take into account the data presented of the country involved.
CONCLUSION
A low S. pneumoniae nasal carriage prevalence was assessed in general practice patients in nine European countries. A large variability in antibiotic resistance was noted among the participating countries, with the highest overall resistance in Spain and the lowest in Sweden.
